XORTX Therapeutics Inc. (XRTX) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering XORTX Therapeutics Inc. (XRTX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For XORTX Therapeutics Inc., analysts forecast revenue falling from $84.40M in 2023 to $16.00M in 2027; the average estimate for 2027 earnings per share is $4.00; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
XORTX Therapeutics Inc. (XRTX) forecast — frequently asked questions
What are analysts forecasting for XORTX Therapeutics Inc.'s earnings?
The average analyst estimate for XORTX Therapeutics Inc. (XRTX) earnings per share in 2027 is 4.00, with individual estimates between 4.00 and 4.00.
How much revenue is XORTX Therapeutics Inc. expected to make?
Analysts forecast XORTX Therapeutics Inc. (XRTX) revenue of $16.00M in 2027, based on 1 published estimates.
How many analysts cover XRTX?
1 analyst contribute estimates for XORTX Therapeutics Inc. (XRTX). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.